| Assessment Status | Rapid Review Complete |
| HTA ID | 22070 |
| Drug | Oral Azacitidine |
| Brand | Onureg® |
| Indication | For maintenance treatment in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation. |
| Assessment Process | |
| Rapid review commissioned | 22/11/2022 |
| Rapid review completed | 23/12/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of oral azacitidine compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations December 2023.
